#Israel #Jerusalem #Immunotherapy #Scinai #Jonathan Sadeh

Dr. Jonathan Sadeh Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Immunotherapeutics Ltd., a biopharmaceutical entity specializing in the development of innovative therapies addressing inflammation and immunology, has announced the appointment of Dr. Jonathan Sadeh to its Scientific Advisory Board (SAB). This strategic move aims to bolster the clinical advancements of the company’s leading IL-17 program and its distinctive VHH antibody pipeline.

A Wealth of Experience

Dr. Sadeh brings over two decades of expertise in drug development and clinical research to Scinai. His previous role as Senior Vice President at Bristol-Myers Squibb (BMS) saw him lead the charge in various therapeutic areas, including immunology, cardiovascular, and neuroscience. During his tenure, he was integral in multiple drug approvals, covering a broad range of fields such as pulmonary care, rheumatology, dermatology, gastroenterology, and neurology.

Among his notable achievements, Dr. Sadeh played a pivotal role in the recent approval of Sotyktu, a groundbreaking TYK2 inhibitor utilized in treating psoriasis. His illustrious career also includes senior leadership positions at renowned companies like Sanofi, AstraZeneca, and Schering-Plough.

Dr. Sadeh holds a Medical Doctorate from the esteemed Mount Sinai School of Medicine, along with a Master of Science in Clinical Research from Harvard Medical School. He completed a distinguished fellowship in pulmonary and critical care at Harvard, marking the beginning of his career as an academic researcher at Brigham and Women's Hospital.

Commitment to Patient-Centric Solutions

In response to his new role, Dr. Sadeh expressed his commitment to developing innovative therapies tailored to patients with significant unmet medical needs. He highlighted Scinai's unique approach of employing VHH antibodies as a means to enhance existing biologics. This method fosters the potential to address patients' conditions more effectively, providing them with meaningful treatment options.

“I am eager to contribute to Scinai’s mission,” stated Dr. Sadeh. “Collaborating with esteemed institutions such as Max Planck and UMG reaffirms my confidence in Scinai’s capabilities and ambitions to become a globally recognized leader in scientifically-driven drug development.”

Leadership's Enthusiasm

Scinai's CEO, Amir Reichman, conveyed his excitement regarding Dr. Sadeh's addition to the SAB. He emphasized that Dr. Sadeh’s extensive background in drug development and clinical research aligns perfectly with Scinai’s vision of advancing its pipeline of novel immunotherapies.

“Dr. Sadeh’s insights and contributions will be invaluable as we continue our efforts to deliver transformative therapies to populations in need,” stated Reichman.

About Scinai Immunotherapeutics

Founded with a mission to revolutionize treatment approaches to inflammation and immunological disorders, Scinai Immunotherapeutics operates with two primary business units: one dedicated to in-house research and development of biologics, and another functioning as a Contract Development and Manufacturing Organization (CDMO). The company aims to deliver cutting-edge therapies by leveraging its innovative nanosized VHH antibodies that target complex diseases.

For more information on Scinai Immunotherapeutics, visit their official website at www.scinai.com.